Clin Exp Vaccine Res.  2020 Jan;9(1):1-7. 10.7774/cevr.2020.9.1.1.

Hepatitis B vaccination and immunotherapies: an update

• Stasi C
• Silvestri
• Voller F

• KMID: 2470832
• DOI: http://doi.org/10.7774/cevr.2020.9.1.1

Abstract

World Health Organization (WHO) estimates that 257 million people were living with chronic hepatitis B virus (HBV) infection. Highest HBV prevalence was found in the WHO Western Pacific Region (6.2%) and in the WHO African Region (6.1%). The HBV vaccine is the best protection against chronic HBV infection and its complications. Globally, routine infant immunization against HBV has increased with an estimated coverage of 84% in 2017. Nevertheless, in many countries further efforts are needed to implement this coverage and ensure national immunization programs for people at major risk for HBV infection. Therapeutic vaccination in chronic HBV infected patients can cause anti-HBV immune responses able to remove and/or cure infected hepatocytes. It shows promising results in murine model and human trials, but these results need to be consolidated by further multicenter clinical studies. In particular, the efficacy of therapeutic vaccine seems to improve by combination therapies.

Keyword

Hepatitis B virus infection; Vaccination; Therapeutic vaccine; Chronic hepatitis B

MeSH Terms

Hepatitis B*
Hepatitis B, Chronic
Hepatitis*
Hepatocytes
Humans
Immunization
Immunization Programs
Immunotherapy*
Infant
Prevalence
Vaccination*
World Health Organization

Reference

1. World Health Organization. Hepatitis B [Internet]. Geneva: World Health Organization;2019. cited 2019 Jul 18. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.

2. World Health Organization Regional officer for Europe. Learn the ABCs of hepatitis before you leave on holiday [Internet]. Copenhagen: World Health Organization Regional officer for Europe;2019. cited 2019 Jul 23. Available from: http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/news/news/2019/7/learn-the-abcs-of-hepatitis-before-you-leave-on-holiday.

3. European Centre for Disease Prevention and Control. Hepatitis B: annual epidemiological report for 2017 [Internet]. Solna: European Centre for Disease Prevention and Control;2019. cited 2019 Jun 17. Available from: https://ecdc.europa.eu/en/publications-data/hepatitis-b-annual-epidemiological-report-2017.

4. World Health Organization. Data and statistics [Internet]. Copenhagen: World Health Organization Regional officer for Europe;2019. cited 2019 Jul 23. Available from: http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/data-and-statistics.

5. Dolan K, Wirtz AL, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016; 388:1089–1102.

6. Stasi C, Silvestri C, Fanti E, Di Fiandra T, Voller F. Prevalence and features of chronic viral hepatitis and HIV coinfection in Italian prisons. Eur J Intern Med. 2016; 34:e21–e22.

7. Sagnelli E, Starnini G, Sagnelli C, et al. Blood born viral infections, sexually transmitted diseases and latent tuberculosis in Italian prisons: a preliminary report of a large multicenter study. Eur Rev Med Pharmacol Sci. 2012; 16:2142–2146.

8. Geue C, Wu O, Xin Y, et al. Cost-effectiveness of HBV and HCV screening strategies: a systematic review of existing modelling techniques. PLoS One. 2015; 10:e0145022.

9. World Health Organization. 2019. Documenting the impact of hepatitis B immunization: best practices for conducting a serosurvey [Internet]. Geneva: World Health Organization;2019. cited 2019 Jul 23. Available from: https://apps.who.int/iris/bitstream/handle/10665/70808/WHO_IVB_11.08_eng.pdf?sequence=1.

10. Ministry of Health. Vaccination for hepatitis B: clarifications to DM 20/11/2000 [Internet]. Rome: Ministry of Health;2000. cited 2019 Jul 23. Available from: http://www.trovanorme.salute.gov.it/normsan-pdf/0000/28940_1.pdf.

11. Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings [Internet]. Atlanta, GA: Centers for Disease Control and Prevention;2003. cited 2019 Jul 23. Available from: https://www.cdc.gov/Mmwr/preview/mmwrhtml/rr5201a1.htm.

12. Almasio PL, Babudieri S, Barbarini G, et al. Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). Dig Liver Dis. 2011; 43:589–595.

13. Van Herck K, Leuridan E, van Damme P. Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance. Sex Transm Infect. 2007; 83:426–432.

14. Stasi C, Monnini M, Cellesi V, et al. Screening for hepatitis B virus and accelerated vaccination schedule in prison: a pilot multicenter study. Vaccine. 2019; 37:1412–1417.

15. Wright NM, Campbell TL, Tompkins CN. Comparison of conventional and accelerated hepatitis B immunisation schedules for homeless drug users. Commun Dis Public Health. 2002; 5:324–326.

16. Wouters K, Leuridan E, van Herck K, et al. Compliance and immunogenicity of two hepatitis B vaccination schedules in sex workers in Belgium. Vaccine. 2007; 25:1893–1900.

17. Mangen MJ, Stibbe H, Urbanus A, et al. Targeted outreach hepatitis B vaccination program in high-risk adults: the fundamental challenge of the last mile. Vaccine. 2017; 35:3215–3221.

18. US Preventive Services Task Force. Owens DK, Davidson KW, et al. Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019; 322:349–354.

19. AIDSinfo. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents [Internet]. Rockville, MD: AIDSinfo;2018. cited 2019 Oct 1. Available from: https://aidsinfo.nih.gov/guidelines/html/4/adultand-adolescent-oiprevention-and-treatment-guidelines/344/hbv.

20. Wilkins E, Nelson M, Agarwal K, et al. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med. 2013; 14 Suppl 4:1–71.

21. Catherine FX, Piroth L. Hepatitis B virus vaccination in HIV-infected people: a review. Hum Vaccin Immunother. 2017; 13:1–10.

22. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection [Internet]. Geneva: World Health Organization;2015. cited 2019 Mar 20. Available from: http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059eng.pdf?ua=1[7].

23. Tang H, Griffin J, Innaimo S, Lehman-Mckeeman L, Llamoso C. The discovery and development of a potent antiviral drug, Entecavir, for the treatment of chronic hepatitis B. J Clin Transl Hepatol. 2013; 1:51–58.

24. Tan ZM, Sun BC. Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence. World J Gastroenterol. 2013; 19:8895–8901.

25. Bourliere M, Kahloun A, Gascou-Tessonnier G. Analogs and fibrosis regression in hepatitis B. Gastroenterol Clin Biol. 2009; 33:923–929.

26. Cai D, Mills C, Yu W, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother. 2012; 56:4277–4288.

27. Zoulim F, Yogaratnam JZ, Vandenbossche JJ, et al. Safety, pharmakokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ-56136379 (JNJ-6379) in treatmentnaive chronic hepatitis B (CHB) patients without cirrhosis. J Hepatol. 2018; 68:S102.

28. Quinet J, Jamard C, Vaillant A, Cova L. Achievement of surface antigen clearance in the liver by combination therapy with REP 2139-Ca and nucleoside analogues against chronic hepatitis B. J Hepatol. 2016; 64:Suppl 2. S285.

29. Tseng TC, Huang LR. Immunopathogenesis of hepatitis B virus. J Infect Dis. 2017; 216(suppl_8):S765–S770.

30. Liang TJ, Block TM, McMahon BJ, et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology. 2015; 62:1893–1908.

31. Lobaina Y, Michel ML. Chronic hepatitis B: immunological profile and current therapeutic vaccines in clinical trials. Vaccine. 2017; 35:2308–2314.

32. Pol S. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Biomed Pharmacother. 1995; 49:105–109.

33. Lai MW, Hsu CW, Lin CL, et al. Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study. Hepatol Int. 2018; 12:456–464.

34. Bian Y, Zhang Z, Sun Z, et al. Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. Hepatology. 2017; 66:1067–1082.

35. Zoulim F, Fournier C, Habersetzer F, et al. Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Hum Vaccin Immunother. 2019; 1–12.

36. Boni C, Janssen HL, Rossi M, et al. Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis. Gastroenterology. 2019; 157:227–241.

37. King TH, Kemmler CB, Guo Z, et al. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS One. 2014; 9:e101904.

38. Al Mahtab M, Akbar SM, Aguilar JC, et al. Treatment of chronic hepatitis B naive patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). PLoS One. 2018; 13:e0201236.

39. Brillanti S, Laterza L, Cecinato P, Bazzoli F. Loss and seroconversion of hepatitis B surface antigen after vaccine therapy in chronic hepatitis B patients treated with nucleoside/nucleotide analogues. Hipatol Int. 2013; 7:S169–S170.